PURPOSE: The aim of this prospective study was to compare in non-Asian subjects the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of two short-acting cardioselective β1-adrenergic antagonists, landiolol and esmolol, after administration of three different bolus dosages. MATERIALS AND METHODS: We conducted a single-center, prospective, double-blinded, randomized study in three cross-over periods with 12 healthy subjects (7 women and 5 men, mean age of 24.5 ± 6.9 years) each receiving three doses of landiolol (0.1, 0.2, and 0.3 mg/kg BW) either in a newly developed concentrate i.v. formulation (Rapibloc® 20 mg/2 mL concentrate) or a lyophilized formulation, or three doses of esmolol (0.5, 1, and 1.5 mg/kg BW) in an i.v. formulation (Brevibloc® 100 mg/10 mL). PK and PD parameters, safety, and tolerability were assessed. FINDINGS: Results of the two landiolol formulations were reported previously and were similar. For the landiolol concentrate formulation and esmolol, maximum blood concentrations were rapidly reached (mean t max ranged between 1.8 and 3.0 min for landiolol and 1.8 to 2.4 min for esmolol). The parent drugs disappeared very fast from the blood stream, with a t 1/2 of 3.2 ± 1.2 (SD) minutes and 3.7 ± 2.1 (SD) minutes for the low doses of landiolol and esmolol, respectively. Despite comparable injection rates (0.1 or 0.5 mg/kg/15 s for landiolol and esmolol, respectively), the onset of significant heart rate reduction occurred earlier in response to landiolol (1 min) than in response to esmolol (2 min). In addition, significantly lower heart rate values were obtained at every dose level of landiolol, in comparison to esmolol (p < 0.05). Both compounds reduced the systolic blood pressure to a comparable degree. Especially at the highest dose, the duration of blood pressure reduction was longer under esmolol compared to landiolol. Seven mild to moderate adverse events occurred after administration of landiolol, and five occurred after administration of esmolol. No serious adverse events were reported in this study. IMPLICATIONS: Heart rate reduction induced by a new liquid formulation of landiolol occurred faster, was more pronounced, and lasted longer than the effects of corresponding standard esmolol doses. Both agents reduced systolic blood pressure to a comparable degree, but the blood pressure decrease lasted longer after esmolol infusion. The local tolerance and safety profiles of the two formulations were similar. In summary, compared to esmolol, landiolol shows a more prominent and pronounced bradycardic effect in relation to its blood pressure-lowering effect, an action profile that might be of specific advantage in the perioperative setting. TRIAL REGISTRATION: NCT01652898 and 2012-002127-14. https://clinicaltrials.gov/ct2/show/NCT01652898?term=landiolol&rank=7.

AOP Orphan Pharmaceuticals AG Wien Austria

Aprova s r o Prague Czech Republic

Center for Pharmacology and Analysis s r o Prague Czech Republic

MRN Medical Research Network GmbH Postgasse 11 22 A 1010 Vienna Austria

Komentář v

Eur J Clin Pharmacol. 2018 May;74(5):671-672. doi: 10.1007/s00228-017-2408-y. PubMed

Zobrazit více v PubMed

Int J Cardiovasc Imaging. 2013 Jun;29 Suppl 1:7-20 PubMed

J Cardiothorac Vasc Anesth. 2006 Dec;20(6):793-5 PubMed

Can J Anaesth. 1991 Mar;38(2):204-9 PubMed

Am J Cardiol. 1991 Jun 15;67(16):1319-23 PubMed

Scand Cardiovasc J. 2005 Sep;39(4):250-4 PubMed

J Cardiothorac Vasc Anesth. 1999 Oct;13(5):555-61 PubMed

Can J Anaesth. 1991 Oct;38(7):849-58 PubMed

J Thorac Cardiovasc Surg. 2012 Nov;144(5):1241-8 PubMed

Gen Thorac Cardiovasc Surg. 2011 Dec;59(12):799-805 PubMed

Eur J Clin Pharmacol. 1994;46(5):399-404 PubMed

Can J Anaesth. 1989 Sep;36(5):593-7 PubMed

Jpn Circ J. 2001 Apr;65(4):275-8 PubMed

J Cardiovasc Pharmacol. 1999 Jul;34(1):70-7 PubMed

J Thorac Cardiovasc Surg. 1990 Aug;100(2):221-7 PubMed

J Clin Anesth. 2015 Mar;27(2):120-8 PubMed

Circ J. 2013;77(4):908-16 PubMed

Clin Pharmacol Ther. 1985 Nov;38(5):579-85 PubMed

J Am Coll Cardiol. 1984 Feb;3(2 Pt 1):394-9 PubMed

Chem Pharm Bull (Tokyo). 1992 Jun;40(6):1462-9 PubMed

Arzneimittelforschung. 1995 May;45(5):536-41 PubMed

Am Heart J. 1991 May;121(5):1347-52 PubMed

Am J Health Syst Pharm. 2009 Aug 1;66(15):1343-52 PubMed

Drugs. 2013 Jun;73(9):959-77 PubMed

J Anesth. 2010 Aug;24(4):503-10 PubMed

Can J Anaesth. 2005 Dec;52(10):1027-34 PubMed

Front Pharmacol. 2013 Dec 02;4:150 PubMed

J Clin Anesth. 1988;1(1):31-5 PubMed

Anesth Analg. 1999 Mar;88(3):477-82 PubMed

J Pharmacol Exp Ther. 1996 Aug;278(2):555-63 PubMed

Circulation. 1985 Oct;72(4):873-80 PubMed

Clin Pharmacol Ther. 1987 Jan;41(1):112-7 PubMed

Can J Anaesth. 2005 Mar;52(3):254-7 PubMed

Anesth Analg. 1990 Jan;70(1):68-71 PubMed

Am J Cardiovasc Drugs. 2013 Oct;13(5):353-64 PubMed

Clin Pharmacol Ther. 1994 Aug;56(2):223-8 PubMed

Can J Anaesth. 1992 Jul;39(6):559-62 PubMed

Can J Anaesth. 1996 Aug;43(8):778-82 PubMed

Drugs R D. 2005;6(6):385-94 PubMed

Am J Cardiol. 1985 Oct 23;56(11):3F-13F PubMed

Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702 PubMed

Anaesthesia. 1997 Aug;52(8):790-4 PubMed

J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1156-60 PubMed

JACC Cardiovasc Interv. 2016 Feb 8;9(3):231-240 PubMed

Anaesth Intensive Care. 2009 Nov;37(6):893-902 PubMed

Can J Anaesth. 1990 Mar;37(2):202-5 PubMed

Clin Drug Investig. 2013 Jul;33(7):505-14 PubMed

Eur J Clin Pharmacol. 1997;51(6):467-71 PubMed

J Cardiovasc Pharmacol. 1983 Jul-Aug;5(4):668-77 PubMed

Clin Drug Investig. 2014 Jan;34(1):53-62 PubMed

Anesth Analg. 1995 Aug;81(2):297-300 PubMed

Anesthesiology. 1987 Mar;66(3):323-6 PubMed

Drug Metab Pharmacokinet. 2005 Oct;20(5):337-44 PubMed

Clin Pharmacol Ther. 1983 Oct;34(4):427-34 PubMed

Biol Pharm Bull. 2012;35(10):1655-60 PubMed

Drug Metab Dispos. 1985 Jul-Aug;13(4):420-4 PubMed

J Cardiothorac Anesth. 1990 Dec;4(6):704-6 PubMed

Anesth Analg. 1990 Dec;71(6):675-8 PubMed

J Pharmacol Exp Ther. 2016 Oct;359(1):73-81 PubMed

Int J Clin Pharmacol Ther Toxicol. 1984 Feb;22(2):112-7 PubMed

Ann Pharmacother. 1994 Jun;28(6):701-3 PubMed

J Clin Anesth. 1995 Feb;7(1):5-8 PubMed

Eur J Pharm Sci. 2016 Sep 20;92 :64-73 PubMed

Can J Anaesth. 2001 Nov;48(10):985-9 PubMed

Anesth Analg. 2000 Jun;90(6):1257-61 PubMed

J Cardiothorac Surg. 2013 Jan 24;8:19 PubMed

Eur J Vasc Endovasc Surg. 2014 Feb;47(2):119-23 PubMed

Anesth Analg. 2007 Jan;104(1):124-9 PubMed

J Anesth. 2008;22(4):361-6 PubMed

Eur J Pharmacol. 1983 Oct 14;94(1-2):43-51 PubMed

J Thorac Cardiovasc Surg. 2011 Jun;141(6):1478-87 PubMed

Adv Ther. 2013 Sep;30(9):803-18 PubMed

Circ J. 2012;76(5):1097-101 PubMed

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01652898